Abstract: A steering system on a marine vessel includes a steering wheel, a wheel sensor configured to measure wheel movement of the steering wheel, a steering actuator configured to rotate a steerable component based on movement of the steering wheel, and a variable resistance device controllable to apply a variable resistance amount to resist movement of the steering wheel. The system further comprises a controller that controls the variable resistance device and is configured to receive the wheel movement measurements by the wheel sensor and determine a resistance amount based on the wheel movement measurements and a corresponding steering response relative to the response capability of the steering system, and then to control the variable resistance device based on the resistance amount.

Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: Described herein is a policy-based Internet Protocol (IP) network wherein the Quality of Service (QoS) provisioning across various network devices is managed by policy processing via a user interface including a graphic user interface. The user interface incorporates information made available by a server, such as lightweight directory access protocol (LDAP) server, having a repository, and thereby allows for a consistent set up voice-over IP devices, video devices and network data devices with minimal entries by the user. Further, the user interfaces allows for efficient policy creation and editing.

Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: Described herein is a policy-based Internet Protocol (IP) network wherein the Quality of Service (QoS) provisioning across various network devices is managed by policy processing via a user interface including a graphic user interface. The user interface incorporates information made available by a server, such as lightweight directory access protocol (LDAP) server, having a repository, and thereby allows for a consistent set up voice-over IP devices, video devices and network data devices with minimal entries by the user. Further, the user interfaces allows for efficient policy creation and editing.

Abstract: Described herein is a policy-based Internet Protocol (IP) network wherein the Quality of Service (QoS) provisioning across various network devices is managed by policy processing via a user interface including a graphic user interface. The user interface incorporates information made available by a server, such as lightweight directory access protocol (LDAP) server, having a repository, and thereby allows for a consistent set up voice-over IP devices, video devices and network data devices with minimal entries by the user. Further, the user interfaces allows for efficient policy creation and editing.

Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: A modular furniture assembly unit includes a box having a length, a width, and a depth, the box having first and second major sides in opposition to each other that define the length and the width of the box, and having third, fourth, fifth, and sixth sides therebetween, the first side having a first connector attached thereto at a distance from the third side of the box substantially equivalent to the depth of the box, the second side of the box having a plurality of second connectors attached near at least three of the third, fourth, fifth, and sixth sides of the box, wherein the first connector is configured to attach to a second connector of an identical box to couple the box to the identical box to form a modular furniture piece. In a further aspect, the first connector is a rotatable clamp and the second connectors are hooks to which the rotatable clamp is connectable.

Abstract: Described herein is a policy-based Internet Protocol (IP) network wherein the Quality of Service (QoS) provisioning across various network devices is managed by policy processing via a user interface including a graphic user interface. The user interface incorporates information made available by a server, such as lightweight directory access protocol (LDAP) server, having a repository, and thereby allows for a consistent set up voice-over IP devices, video devices and network data devices with minimal entries by the user. Further, the user interfaces allows for efficient policy creation and editing.

Abstract: Described herein is a policy-based Internet Protocol (IP) network wherein the Quality of Service (QoS) provisioning across various network devices is managed by policy processing via a user interface including a graphic user interface. The user interface incorporates information made available by a server, such as lightweight directory access protocol (LDAP) server, having a repository, and thereby allows for a consistent set up voice-over IP devices, video devices and network data devices with minimal entries by the user. Further, the user interfaces allows for efficient policy creation and editing.

Abstract: The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.

Abstract: The present invention provides methods for inhibiting the anticoagulation effect of a thrombin inhibitor in a patient in need thereof comprising administration of a therapeutically effective amount of a variant prothrombin or thrombin that is capable of binding the thrombin inhibitor and that has reduced procoagulant activity. Variant prothrombins or thrombins of use in the methods of the present invention include thrombin mutants W215A, W215A/E217A, or variants thereof in which the amino acids at positions 215 and/or 217 are alanine. Methods are also provided in which the thrombin mutants are administered with an additional active agent, particularly hemostatic agents such as activated factor VII or activated prothrombin complex concentrate. In one embodiment of the invention, the methods are useful in the treatment of patients in which a direct thrombin inhibitor has been administered, particularly argatroban.

Abstract: Described herein is a policy-based Internet Protocol (IP) network wherein the Quality of Service (QoS) provisioning across various network devices is managed by policy processing via a user interface including a graphic user interface. The user interface incorporates information made available by a server, such as lightweight directory access protocol (LDAP) server, having a repository, and thereby allows for a consistent set up voice-over IP devices, video devices and network data devices with minimal entries by the user. Further, the user interfaces allows for efficient policy creation and editing.